Commercialization Phase Initiated with EU Approval

The European Union Executive Committee approved Eli Lilly and Company's (LLY) Omvoh (mirikizumab) on May 26, 2023, for the treatment of moderate to severe active ulcerative colitis in adults. The target population includes patients who have not responded adequately to, or have lost response to, or are intolerant of existing therapies or biologics. Following the positive opinion adopted by the EMA's Committee for Medicinal Products for Human Use (CHMP) on March 30, 2023, centralized marketing authorization was granted, and the approval status corresponds to the marketed phase.

Differentiation through IL-23p19 Selective Blockade

Mirikizumab, the active ingredient in Omvoh, is a humanized monoclonal antibody that selectively blocks the p19 subunit of interleukin-23 (IL-23), which regulates inflammatory T-cell responses. Standard treatments include 5-ASA agents such as mesalazine and corticosteroids. In the moderate to severe patient market, competitors include Entyvio (vedolizumab, α4β7 integrin), Stelara (ustekinumab, IL-12/23 p40), Rinvoq (upadacitinib, JAK1), and Zeposia (ozanimod, S1P). Omvoh combines IL-23p19 selectivity with intravenous induction followed by subcutaneous maintenance therapy, targeting even patients who have failed biologic therapies.

Efficacy Proven in Phase 3 LUCENT Trials

Approval was based on results from the randomized, double-blind, placebo-controlled Phase 3 LUCENT-1 and LUCENT-2 trials. In the 12-week induction trial, clinical remission rates were 24.2% for Omvoh and 13.3% for placebo. In the 40-week maintenance trial among induction responders, the rates were 49.9% and 25.1%, respectively. At the one-year mark, histological and endoscopic mucosal remission rates were 43.3% for Omvoh and 21.8% for placebo, supporting the drug's ability to sustain both symptom improvement and mucosal inflammation control.

Reimbursement Will Determine Market Penetration Speed

The global ulcerative colitis treatment market was approximately USD 8.17 billion in 2023 and is projected to grow to USD 11.39 billion by 2030. While EU approval removes a key regulatory barrier for access to major markets, actual prescription expansion will depend on country-specific health technology assessments, drug pricing negotiations, and the sequence of biologic therapy use. In addition to the prescribing base established by Stelara and Entyvio, competition from JAK inhibitors and later IL-23p19 antibodies means that Omvoh's long-term durability and breadth of reimbursement will be key variables in determining market share.

Expansion of Global Regulatory Validation

In Japan, Omvoh was approved in March 2023 after review by the PMDA. The U.S. FDA approved Omvoh for the same indication on October 26, 2023. The consecutive approvals in the EU, Japan, and the U.S. signify that the LUCENT clinical package and manufacturing and quality data have been accepted in major regulatory regions. Subsequently, the EU indication was expanded to include Crohn's disease, and mirikizumab has now become a commercial asset covering both major inflammatory bowel diseases.